{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Seizure%2C+Partial&page=2",
    "query": {
      "condition": "Seizure, Partial",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Seizure%2C+Partial&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T08:13:53.046Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00567424",
      "title": "GW273225 Therapy Added To Current Seizure Treatments In Patients With Partial Seizures",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epilepsy"
      ],
      "interventions": [
        {
          "name": "GW273225",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2006-07",
      "completion_date": "2008-03",
      "has_results": false,
      "last_update_posted_date": "2013-04-04",
      "last_synced_at": "2026-05-22T08:13:53.046Z",
      "location_count": 30,
      "location_summary": "Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 26 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "San Jose",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00567424"
    },
    {
      "nct_id": "NCT02090998",
      "title": "Sphenopalatine Ganglion Nerve Block vs. Elavil for Treatment of Transformed Migraines",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Transformed Migraine",
        "Chronic Daily Headache"
      ],
      "interventions": [
        {
          "name": "SPG Block with 5% Lidocaine gel",
          "type": "PROCEDURE"
        },
        {
          "name": "Amitriptyline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2014-05",
      "completion_date": "2020-03-16",
      "has_results": true,
      "last_update_posted_date": "2024-07-16",
      "last_synced_at": "2026-05-22T08:13:53.046Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02090998"
    },
    {
      "nct_id": "NCT01262677",
      "title": "Once-A-Day Pregabalin For Partial Seizures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Partial Seizures",
        "Epilepsies, Partial"
      ],
      "interventions": [
        {
          "name": "pregabalin",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 325,
      "start_date": "2011-02-17",
      "completion_date": "2012-08-01",
      "has_results": true,
      "last_update_posted_date": "2021-01-25",
      "last_synced_at": "2026-05-22T08:13:53.046Z",
      "location_count": 26,
      "location_summary": "Northport, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 15 more",
      "locations": [
        {
          "city": "Northport",
          "state": "Alabama"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Murrieta",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01262677"
    },
    {
      "nct_id": "NCT00044278",
      "title": "Pediatric Epilepsy Study in Subjects 1-24 Months",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epilepsy"
      ],
      "interventions": [
        {
          "name": "lamotrigine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "24 Months",
        "sex": "ALL",
        "summary": "1 Month to 24 Months"
      },
      "enrollment_count": 197,
      "start_date": "2000-09",
      "completion_date": "2006-06",
      "has_results": false,
      "last_update_posted_date": "2017-01-18",
      "last_synced_at": "2026-05-22T08:13:53.046Z",
      "location_count": 41,
      "location_summary": "Mobile, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 36 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00044278"
    },
    {
      "nct_id": "NCT00871377",
      "title": "Double Blind, Crossover Study of Fish Oil [EPA and DHA] for Intractable Partial Seizures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epilepsy"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "High Dose Fish Oil",
          "type": "DRUG"
        },
        {
          "name": "Low Dose Fish Oil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Center for Complementary and Integrative Health (NCCIH)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 24,
      "start_date": "2008-05",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2014-02-07",
      "last_synced_at": "2026-05-22T08:13:53.046Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00871377"
    },
    {
      "nct_id": "NCT02849626",
      "title": "Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Partial-Onset or Primary Generalized Tonic-Clonic Seizures"
      ],
      "interventions": [
        {
          "name": "Perampanel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "4 Years to 12 Years"
      },
      "enrollment_count": 180,
      "start_date": "2016-11-16",
      "completion_date": "2021-12-06",
      "has_results": true,
      "last_update_posted_date": "2022-10-28",
      "last_synced_at": "2026-05-22T08:13:53.046Z",
      "location_count": 29,
      "location_summary": "Little Rock, Arkansas • Palo Alto, California • Aurora, Colorado + 25 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gulf Breeze",
          "state": "Florida"
        },
        {
          "city": "Loxahatchee Groves",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02849626"
    },
    {
      "nct_id": "NCT00368472",
      "title": "4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epilepsy"
      ],
      "interventions": [
        {
          "name": "Perampanel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 138,
      "start_date": "2006-10",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2015-12-10",
      "last_synced_at": "2026-05-22T08:13:53.046Z",
      "location_count": 12,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00368472"
    },
    {
      "nct_id": "NCT05481905",
      "title": "ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Focal Epilepsy"
      ],
      "interventions": [
        {
          "name": "ENX-101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Engrail Therapeutics INC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 0,
      "start_date": "2022-09",
      "completion_date": "2024-12",
      "has_results": false,
      "last_update_posted_date": "2023-07-06",
      "last_synced_at": "2026-05-22T08:13:53.046Z",
      "location_count": 38,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Downey, California + 31 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05481905"
    },
    {
      "nct_id": "NCT03283371",
      "title": "Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epilepsy, Focal Seizures, Partial Seizures"
      ],
      "interventions": [
        {
          "name": "Natalizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 67,
      "start_date": "2018-03-20",
      "completion_date": "2020-11-18",
      "has_results": true,
      "last_update_posted_date": "2021-12-14",
      "last_synced_at": "2026-05-22T08:13:53.046Z",
      "location_count": 31,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 26 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03283371"
    },
    {
      "nct_id": "NCT05716100",
      "title": "A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Focal Onset Seizures"
      ],
      "interventions": [
        {
          "name": "XEN1101",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Xenon Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 360,
      "start_date": "2023-05-09",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-14",
      "last_synced_at": "2026-05-22T08:13:53.046Z",
      "location_count": 19,
      "location_summary": "Little Rock, Arkansas • Downey, California • Los Angeles, California + 16 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Gulf Breeze",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05716100"
    }
  ]
}